Related references
Note: Only part of the references are listed.Reference values for plasma neurofilament light chain (NfL) in healthy Chinese
Jingshan Chen et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
Orhan Aktas et al.
ANNALS OF NEUROLOGY (2021)
Low-dose rituximab treatment for new-onset generalized myasthenia gravis
Huining Li et al.
JOURNAL OF NEUROIMMUNOLOGY (2021)
Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies
Xuechun Chang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein
Jae-Won Hyun et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity
Heidi Hogel et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders
Marius Ringelstein et al.
NEUROLOGY (2020)
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Benedicte Delcoigne et al.
NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease
Hyunjin Kim et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course
Andre Huss et al.
FRONTIERS IN NEUROLOGY (2020)
Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases
Eun-Jae Lee et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
NfL as a biomarker for neurodegeneration and survival in Parkinson disease
David Backstrom et al.
NEUROLOGY (2020)
Serum neurofilament light as a biomarker in progressive multiple sclerosis
Raju Kapoor et al.
NEUROLOGY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle et al.
NEUROLOGY (2019)
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson et al.
JAMA NEUROLOGY (2019)
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
Katja Akguen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD
Mitsuru Watanabe et al.
NEUROLOGY (2019)
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
Ester Canto et al.
JAMA NEUROLOGY (2019)
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients
Tobias Sejbaek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial
Pierre de Flon et al.
ACTA NEUROLOGICA SCANDINAVICA (2019)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder
I. H. Jeong et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica
Chun-Sheng Yang et al.
NEUROLOGY (2013)
Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases
A. Petzold et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2011)
The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
Mithu Storoni et al.
PLOS ONE (2011)
Astrocytic damage is far more severe than demyelination in NMO A clinical CSF biomarker study
R. Takano et al.
NEUROLOGY (2010)
Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker
T. Misu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis
T. Misu et al.
BRAIN (2007)
Share Paper
